BACKGROUND: Small-scale studies correlated the presence of thyroid autoimmunity with both improved or worsened breast cancer outcome. OBJECTIVES: We aimed to clarify this association in a large cohort using the phase III, randomized, controlled Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001). METHODS:TACT women >18 years old with node-positive or high-risk node-negative early breast cancer (pT1-3a, pN0-1, M0), with stored plasma (n = 1,974), taken 15.5 (median; IQR 7.0-24.0) months after breast surgery were studied. Patients had also received chemotherapy (100%), radiotherapy (1,745/1,974; 88.4%), hormonal therapy (1,378/ 1,974; 69.8%), or trastuzumab (48/1,974; 2.4%). History of thyroid diseases and/or related treatments was not available. The prognostic significance of autoantibodies to thyroid peroxidase (TPOAb; positive ≥6 kIU/L), free-thyroxine and thyrotropin (combined: euthyroid, hypothyroid, hyperthyroid) was evaluated for disease-free survival (DFS), overall-survival (OS), and time-to-recurrence (TTR), with Cox regression models in univariate and multivariable analyses. The extended median follow-up was 97.5 months. RESULTS: No difference in DFS was found by TPOAb status (unadjusted hazard ratio [HR]: 0.97, 95%CI: 0.78-1.19; p = 0.75) and/or thyroid function (unadjusted HR [hypothyroid vs. euthyroid]: 1.15, 95% CI: 0.79-1.68; p = 0.46; unadjusted HR [hyperthyroid vs. euthyroid]: 1.14, 95% CI: 0.82-1.61; p = 0.44). Similar results were obtained for OS, TTR, multivariable analyses, when TPOAb titre by tertiles was considered, and in a subgroup of 123 patients with plasma collected before adjuvant treatments. CONCLUSIONS: No evidence for a prognostic role of TPOAb and/or thyroid function in moderate-to-high-risk early breast cancer was found in the largest and longest observational study to date.
RCT Entities:
BACKGROUND: Small-scale studies correlated the presence of thyroid autoimmunity with both improved or worsened breast cancer outcome. OBJECTIVES: We aimed to clarify this association in a large cohort using the phase III, randomized, controlled Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001). METHODS: TACT women >18 years old with node-positive or high-risk node-negative early breast cancer (pT1-3a, pN0-1, M0), with stored plasma (n = 1,974), taken 15.5 (median; IQR 7.0-24.0) months after breast surgery were studied. Patients had also received chemotherapy (100%), radiotherapy (1,745/1,974; 88.4%), hormonal therapy (1,378/ 1,974; 69.8%), or trastuzumab (48/1,974; 2.4%). History of thyroid diseases and/or related treatments was not available. The prognostic significance of autoantibodies to thyroid peroxidase (TPOAb; positive ≥6 kIU/L), free-thyroxine and thyrotropin (combined: euthyroid, hypothyroid, hyperthyroid) was evaluated for disease-free survival (DFS), overall-survival (OS), and time-to-recurrence (TTR), with Cox regression models in univariate and multivariable analyses. The extended median follow-up was 97.5 months. RESULTS: No difference in DFS was found by TPOAb status (unadjusted hazard ratio [HR]: 0.97, 95%CI: 0.78-1.19; p = 0.75) and/or thyroid function (unadjusted HR [hypothyroid vs. euthyroid]: 1.15, 95% CI: 0.79-1.68; p = 0.46; unadjusted HR [hyperthyroid vs. euthyroid]: 1.14, 95% CI: 0.82-1.61; p = 0.44). Similar results were obtained for OS, TTR, multivariable analyses, when TPOAb titre by tertiles was considered, and in a subgroup of 123 patients with plasma collected before adjuvant treatments. CONCLUSIONS: No evidence for a prognostic role of TPOAb and/or thyroid function in moderate-to-high-risk early breast cancer was found in the largest and longest observational study to date.
Authors: Anna G Angelousi; Valsamo K Anagnostou; Michael K Stamatakos; Georgios A Georgiopoulos; Konstantinos C Kontzoglou Journal: Eur J Endocrinol Date: 2011-10-24 Impact factor: 6.664
Authors: P L Fitzgibbons; D L Page; D Weaver; A D Thor; D C Allred; G M Clark; S G Ruby; F O'Malley; J F Simpson; J L Connolly; D F Hayes; S B Edge; A Lichter; S J Schnitt Journal: Arch Pathol Lab Med Date: 2000-07 Impact factor: 5.534
Authors: Alf Inge Hellevik; Bjørn Olav Asvold; Trine Bjøro; Pål R Romundstad; Tom Ivar L Nilsen; Lars J Vatten Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-01-20 Impact factor: 4.254
Authors: A J Hedley; S J Jones; D J Spiegelhalter; P Clements; P D Bewsher; J G Simpson; R D Weir Journal: Lancet Date: 1981-01-17 Impact factor: 79.321
Authors: Sang Soo Kim; In Joo Kim; Seong-Jang Kim; Jee Yeon Lee; Young Tae Bae; Yun Kyung Jeon; Bo Hyun Kim; Yong Ki Kim Journal: J Nucl Med Date: 2012-11-08 Impact factor: 10.057
Authors: Lauren McVicker; Christopher R Cardwell; Stuart A McIntosh; Úna C McMenamin Journal: Breast Cancer Res Treat Date: 2022-07-31 Impact factor: 4.624
Authors: Anne Mette Falstie-Jensen; Buket Ö Esen; Anders Kjærsgaard; Ebbe L Lorenzen; Jeanette D Jensen; Kristin V Reinertsen; Olaf M Dekkers; Marianne Ewertz; Deirdre P Cronin-Fenton Journal: Breast Cancer Res Date: 2020-10-13 Impact factor: 6.466
Authors: Bence Bakos; András Kiss; Kristóf Árvai; Ádám Tabák; Péter Lakatos; Balázs Szili; Barbara Deák-Kocsis; Bálint Tobiás; Zsuzsanna Putz; Richárd Ármós; Bernadett Balla; János Kósa; Magdolna Dank; Zsuzsanna Valkusz; István Takács Journal: BMC Cancer Date: 2021-06-15 Impact factor: 4.430
Authors: Bernhard J Jank; Markus Haas; Julia Schnoell; Michaela Schlederer; Gregor Heiduschka; Lukas Kenner; Lorenz Kadletz-Wanke Journal: J Pers Med Date: 2021-12-08